1. |
Dudeja V, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol, 2015, 42(1): 70-85.
|
2. |
Ehab A, Ayman EN, Ehab EH, et al. Pancreatic cystic neoplasms: predictors of malignant behavior and management. Saudi J Gastroenterol, 2013, 19(1): 45-53.
|
3. |
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut, 2018, 67(5): 789-804.
|
4. |
van Huijgevoort N, Del Chiaro M, Wolfgang CL, et al. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 676-689.
|
5. |
Plichta JK, Brosius JA, Pappas SG, et al. The changing spectrum of surgically treated cystic neoplasms of the pancreas. HPB Surg, 2015, 2015: 791704.
|
6. |
Pozzi-Mucelli RM, Rinta-Kiikka I, Wünsche K, et al. Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol. Eur Radiol, 2017, 27(1): 41-50.
|
7. |
Du C, Chai NL, Linghu EQ, et al. Comparison of endoscopic ultrasound, computed tomography and magnetic resonance imaging in assessment of detailed structures of pancreatic cystic neoplasms. World J Gastroenterol, 2017, 23(17): 3184-3192.
|
8. |
Wu J, Wang Y, Li Z, et al. Accuracy of Fukuoka and American Gastroenterological Association Guidelines for predicting advanced neoplasia in pancreatic cyst neoplasm: a meta-analysis. Ann Surg Oncol, 2019, 26(13): 4522-4536.
|
9. |
田孝东, 杨尹默. 保守观察还是手术切除: 胰腺囊性肿瘤外科治疗策略. 浙江医学, 2017, 39(1): 4-6, 11.
|
10. |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471.
|
11. |
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery, 2007, 142(5): 761-768.
|
12. |
Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery, 2005, 138(1): 8-13.
|
13. |
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology, 2017, 17(5): 738-753.
|
14. |
Kwon RS. Advances in the diagnosis of cystic neoplasms of the pancreas. Curr Opin Gastroenterol, 2012, 28(5): 494-500.
|
15. |
Farrell JJ. Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver, 2015, 9(5): 571-589.
|
16. |
Sethi V, Giri B, Saluja A, et al. Insights into the pathogenesis of pancreatic cystic neoplasms. Dig Dis Sci, 2017, 62(7): 1778-1786.
|
17. |
Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg, 2004, 239(5): 651-657.
|
18. |
Lan C, Li X, Wang X, et al. A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biol Med, 2018, 15(1): 70-78.
|
19. |
Brugge WR. Diagnosis and management of cystic lesions of the pancreas. J Gastrointest Oncol, 2015, 6(4): 375-388.
|
20. |
Lee HJ, Kim MJ, Choi JY, et al. Relative accuracy of CT and MRI in the differentiation of benign from malignant pancreatic cystic lesions. Clin Radiol, 2011, 66(4): 315-321.
|
21. |
Jang DK, Song BJ, Ryu JK, et al. Preoperative diagnosis of pancreatic cystic lesions: the accuracy of endoscopic ultrasound and cross-sectional imaging. Pancreas, 2015, 44(8): 1329-1233.
|
22. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1 000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
|
23. |
Hwang DW, Jang JY, Lim CS, et al. Determination of malignant and invasive predictors in branch duct type intraductal papillary mucinous neoplasms of the pancreas: a suggested scoring formula. J Korean Med Sci, 2011, 26(6): 740-746.
|
24. |
Cao S, Hu Y, Gao X, et al. Serum carbohydrate antigen 19-9 in differential diagnosis of benign and malignant pancreatic cystic neoplasms: a meta-analysis. PLoS One, 2016, 11(11): e0166406.
|
25. |
Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res, 2008, 68(5): 1443-1450.
|
26. |
Zhang X, Zhang W, Feng LJ. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS One, 2014, 9(11): e111906.
|
27. |
Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol, 2015, 22(2): 670-676.
|
28. |
Goh KP, Tan DM, Chan CY, et al. Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms. J Surg Oncol, 2015, 112(4): 366-371.
|
29. |
林侃如, 朱剑清, 李骥, 等. 胰腺浆液性囊腺瘤 161 例诊治体会及术前误诊原因分析. 中华外科杂志, 2018, 56(8): 591-596.
|